Skip to main content
Signal8

Amplia Therapeutics Limited (INNMF)

Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases. Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions. Another compound, AMP886, is also under development for potential applications in cancer and fibrotic disorders. Amplia Therapeutics maintains a strategic collaboration with the Garvan Institute of Medical Research in Sydney, and the company adopted its current name in September 2018, having previously operated as Innate Immunotherapeutics Limited.

Sector: Biotechnology

Industry: Biotechnology

Amplia Therapeutics Limited logo

Amplia Therapeutics Limited

OTC:INNMFHealthcare
-15.56%$0.0535
CLOSED
Mkt Cap$27.46M
EV-
Float479.04M
O/S513.31M
VOL475 sh
$ Vol$25
RVOL0.04×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Amplia Therapeutics Limited logoOTC:INNMFClosed$0.0535-15.56%
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 479.04M · FMP free float

55.4K
Oct 30 (18d)prev 68.9K▼ 19.6%
4.46
Oct 30 (18d)prev 1.18▲ 278.0%
Borrow (IBKR)

The cost to borrow INNMF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
100.0%
Nov 12 (5d)prev 87.8%▲ 12.2 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202655.4K sh
Oct 15, 202668.9K sh
Sep 30, 202661.3K sh
Sep 15, 202665.3K sh
Aug 31, 202665.3K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 12
Latest sessions
DateReported short
Nov 12, 2026100.0%
Nov 9, 202687.8%
Oct 19, 202638.9%
Oct 16, 202666.7%
Oct 13, 202627.4%
36-session median 78.9%mean 76.2%range 7.4–100.0%

130 calendar days requested; 37 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for INNMF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 55,362 INNMF shares were sold short (0.01% of a 479.04M-share float, 4.46 days to cover).